Pacific Biomarkers, Inc. provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. Today, PBI announced they have been awarded major research contracts with two multinational pharmaceutical companies to provide clinical biomarker services.
The studies conducted by PBI will involve analysis of biomarkers associated with cardiovascular, metabolic and inflammatory diseases and hepatic and renal injury. Testing for the new contracts will begin as early as Feb. of this year with estimated total revenue to be over $1 million during the life of the contracts.
One of the leaders at PBI is Amar Sethi, MD, PhD, who serves as the Vice President of Research and Development for the young company. Commenting on what these contracts mean to the global exposure of PBI, Dr. Sethi was quoted as saying, “Our experience and knowledge in drug development, biomarker assay development and clinical trial laboratory support enable us to help our clients by providing the most appropriate biomarkers combined with the best assays for those biomarkers. This important capability allows PBI to support emerging therapeutics related to cardiovascular disease and diabetes where conventional biomarkers and assays may not be adequate.”
PBI Chief Executive Officer Ron Helm went on to add, “Our selection for these projects is validation for our worldwide, best-in-class testing of biomarkers as they relate to the diagnosis and treatment of diseases and the detection of organ injury.”
To learn more about PBI, visit the company website at www.pacbio.com